News Center

KW-136 in Combination with Sofosbuvir Under Phase 3 Trial


In May 2017, Kawin Technology initiated a phase 3 trial program to investigate use of KW-136, an investigational DAA against HCV, in combination with sofosbuvir for treatment of pan-genotypic HCV infection. This regimen is expected to provide the first-in-China, all-oral, pan-genotypic treatment for HCV- infected patients, including those with cirrhosis.

Long-acting Interferon Granted Priority Review Multiple Formulations Recertified by GMP

+86 10 87120888